Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 7/20 | 0.47 |
| ▸ | NPC1 | O15118 | 6/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4096627 | 0.87 | HCRTR1 (0.44) | SMN1; SMN2RAB9ANPC1TP53MAPT | |
| SCHEMBL13871093 | 0.85 | USP30 (0.50) | SMN1; SMN2RAB9ANPC1TP53THRB | |
| SCHEMBL4111865 | 0.83 | SMN1; SMN2 (0.43) | SMN1; SMN2RAB9ANPC1TP53THRB | |
| SCHEMBL4107744 | 0.83 | SMN1; SMN2 (0.43) | SMN1; SMN2RAB9ANPC1TP53THRB | |
| SCHEMBL4107748 | 0.83 | SMN1; SMN2 (0.43) | SMN1; SMN2RAB9ANPC1TP53THRB | |
| SCHEMBL8038359 | 0.82 | SMN1; SMN2 (0.42) | SMN1; SMN2RAB9ANPC1TP53THRB | |
| SCHEMBL4229285 | 0.81 | NPC1 (0.32) | RAB9ANPC1ALDH1A1 | |
| SCHEMBL4101846 | 0.75 | SMN1; SMN2 (0.47) | SMN1; SMN2RAB9ANPC1TP53THRB | |
| SCHEMBL13871099 | 0.74 | USP30 (0.41) | SMN1; SMN2RAB9ANPC1TP53MAPT | |
| SCHEMBL4106727 | 0.72 | NPC1 (0.41) | SMN1; SMN2RAB9ANPC1TP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111820-A1 | FUSED PYRROLIDINE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | claimed |
| US-20090111820-A1 | FUSED PYRROLIDINE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111820-A1 | FUSED PYRROLIDINE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | GRM5, GRIK5, GRM1 | SMN1; SMN2 2221/4885RAB9A 1196/4885NPC1 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.